Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.

scientific article published in May 1998

Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/515267
P698PubMed publication ID9593014
P5875ResearchGate publication ID247554498

P50authorStanley PlotkinQ7599873
P2093author name stringLang J
Jaussaud R
Blondeau C
Strady A
Lienard M
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectrabies vaccineQ4007169
rabiesQ39222
antibodyQ79460
P304page(s)1290-1295
P577publication date1998-05-01
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleAntibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy.
P478volume177

Reverse relations

cites work (P2860)
Q92263180A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children
Q35874598A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines
Q45259927Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV).
Q39477334Chapter 10 Viral infections of lower motor neurons.
Q39414342Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention
Q37635370Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals
Q33889587Immunization for children traveling abroad
Q35104193Immunizations for international travel
Q48025647Immunogenicity and booster efficacy of pre-exposure rabies vaccination
Q54952983Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec.
Q44447203Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium
Q83728751Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS (®)) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio (®)) given as a booster dose at 6 years of
Q44763423Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial
Q92210200Inactivated Rabies Virus-Vectored Immunocontraceptive Vaccine in a Thermo-Responsive Hydrogel Induces High and Persistent Antibodies against Rabies, but Insufficient Antibodies against Gonadotropin-Releasing Hormone for Contraception
Q28829448Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil
Q35191228Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose
Q73407798Pre-exposure rabies vaccination: strategies and cost-minimization study
Q73713357Predictive factors for the neutralizing antibody response following pre-exposure rabies immunization: validation of a new booster dose strategy
Q35714659Rabies and other lyssavirus diseases
Q46302578Rabies in France: an update
Q39246037Rabies in travelers
Q50495857Rabies neutralizing antibody after 2 intradermal doses on days 0 and 21 for pre-exposure prophylaxis.
Q39084014Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans
Q57235772Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults
Q37445181Report of the Fifth AREB Meeting Ho Chi Minh City, Vietnam, 17-20 November 2008.
Q42183661Safety and immunogenicity of chromatographically purified Vero cell rabies vaccine for intradermal pre- and post-exposure rabies prophylaxis
Q40285685Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.
Q50740222Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity.
Q57029804Tollwut: Epidemiologie, prä- und postexpositionelle Immunisierung
Q34392982Travel vaccines and elderly persons: review of vaccines available in the United States.
Q40611647Vaccination in Travelers
Q47923939Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man.

Search more.